Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

The approvals add two more options for psoriasis patients hoping to stay away from biologics as long as they can. If symptoms remain mild to moderate, patients can stay on these drugs indefinitely.

A decade-long study found that obesity was associated with a significantly increased risk for biologic treatment failure in ...

“The results of this study, combined with the established efficacy of biologics for psoriasis,30 suggest that biologics targeting IL-12, IL-23, and IL-17 could be favored over other agents to ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Biologics targeting interleukin-12, -23, and -17 were ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

Moreover, some infections may exacerbate or trigger psoriasis, such as strep throat. Regardless of whether you are on a biologic or immunosuppressive medication for psoriasis, it’s essential to ...